Fewer than a tenth of patients who could benefit from GLP-1 drugs like Wegovy can access them, warns the global health agency as it publishes its initial recommendations on the medications.
Considering over a billion people worldwide currently living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Based on forecasts, over two billion could be obese by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a long-term condition that can be treated with holistic and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key barriers to broad availability to the jabs that can aid individuals in losing considerable weight, says the body.
Skinny Jab Shortage
Even under the present best projected scenario, the supply of GLP-1 therapies might only reach around 100 million people – fewer than 10% of the global need, as stated by the health organization.
The recommendation calls on nations and manufacturers to expand availability, by strategies like licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Jabs Work
The injections imitate a biological compound to reduce digestion speed, reduce hunger and increase the sense of being full so users consume fewer calories.
Patients commonly begin shedding pounds within a few weeks of beginning the weekly injections.
Studies suggests users may regain a significant portion after a year of discontinuing the medication, as their normal hunger come back.
Being overweight or obese elevates your likelihood for developing medical conditions, including diabetes, heart disease, brain attack, and specific malignancies.
Excess weight concerns people in all nations and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
